|
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer. |
|
|
Stock and Other Ownership Interests - Compugen; Harpoon therapeutics; Kleo Pharmaceuticals; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics |
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Compugen; F-Star; Ferring; Genocea Biosciences; Janssen Oncology; Kleo Pharmaceuticals; Merck; Merck Serono; Pfizer; Pierre Fabre; Roche/Genentech; Shattuck Labs; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst) |
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst) |
Travel, Accommodations, Expenses - AACR; ASCO; Merck Sharp & Dohme; Pfizer; Roche/Genentech |
|
|
Honoraria - AstraZeneca/MedImmune; Merck; Sanofi |
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Seagen |
Speakers' Bureau - Merck Sharp & Dohme; Sanofi |
Research Funding - AstraZeneca/MedImmune (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
Stock and Other Ownership Interests - Regeneron |
Patents, Royalties, Other Intellectual Property - Regeneron |
|
|
|
Stock and Other Ownership Interests - Agenus; Amicus Therapeutics; Bellicum Pharmaceuticals; Cel-Sci; Celldex; Gilead Sciences; Merck; Navidea; Newlink Genetics; Progenics; Sarepta Therapeutics; Soligenix; Sorrento Therapeutics; Veracyte |
Travel, Accommodations, Expenses - Regeneron |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Regeneron |